To respond to the public panic, government and private research organizations of every country keep working on the COVID-19 pandemic, even though still there is a lack of more efficacious medicine for the choice of Coronavirus disease treatment. To counteract on this situation several approved drugs including anti-malarial (hydroxychloroquine and chloroquine), and few anti-viral (remdesvir) agents are choice of treatment for COVID-19. However, these agents suffer from certain limitation in their uses and pointed that there is no specific treatment or vaccine available to counter this contagious disease. Hence, there is urgent requirement to find a specific cure for the disease. In this view, there are several ongoing clinical trials of both western and traditional medicines. In present study, phytochemicals from Camellia sinensis were retrieved from the database and identified based on their ability to inhibit matrix metalloproteinase (MMPs) against SARS-CoV-2 main protease. Camellia sinensis entails of a massive number of phytochemicals with a good source of polyphenols such as Catechin, Epicatechin, Epigallocatechin and (-)-Epigallocatechin gallate. Molecular docking was performed using the GLIDE docking module of Schrodinger Suite software. The analysis displayed docking score for the five polyphenols i.e. theaflavin (− 8.701), 1-O-caffeoylquinic acid (− 7.795), Genistein (− 7.168), Epigallocatechin 3-gallate (− 6.282) and Ethyl trans-caffeate (− 5.356). Interestingly, theaflavin and Epigallocatechin 3-gallate have not revealed any side effects. These polyphenolic compounds had a strong binding affinity with hydrogen bonds and a good drug-likeness score. Therefore, Camellia sinensis could be the beneficial option in the prophylaxis of the COVID-19 outbreak.

No abstract

No abstract

Anti-diabetic activity of the plants may follow one or the other mechanism such as their ability to restore the pancreatic tissue function or increase in insulin output or inhibiting the intestinal absorption of glucose or inhibiting the pancreatic enzymes like alpha-amylase, alpha-glucosidase, etc. The alpha-amylase and alpha-glucosidase inhibition assays were performed to analyze the anti-diabetic potential of Acacia suma. RP-HPLC method was developed and validated for simultaneous estimation of Epigallocatechin (EGC), Fisetin (FT), and Quercetin (QT) in hydroalcoholic extract (HAE) of Acacia suma and formulations. The simultaneous estimation was performed using the Luna C18 column with 20µl sample injection volume. Whereas, acetonitrile and phosphate buffer (0.1%, 30:70 v/v, pH 2.7) was used for resolution as mobile phase with column temperature 40 OC and flow rate 1 ml/min. The IC50 for alpha-amylase inhibition and alpha-glucosidase inhibition activity was found to be 12.5µg/ml and 93.79µg/ml respectively was compared with standards. The developed method was found simple, specific, precise and linear with regression coefficient (R2 = 0.999) over the selected range of concentration (2.5-160 μg/mL) having detection limits 0.076, 0.012, 0.010 μg/mL and quantification limits 0.231, 0.038, 0.031 μg/mL for EGC, FT and QT respectively. In-vitro alpha-amylase and alpha-glucosidase inhibition assay support the traditional claim of the plant in the treatment of metabolic disorders. The established RP-HPLC method demonstrates the precise and easy determination of EGC, FT, and QT and is effectively studied by a gradient elution system.